AI Article Synopsis
- The 5-year survival rate for ovarian cancer is significantly higher (90%) in stages I and II compared to only 30% in stages III and IV, with the majority of patients diagnosed at later stages.
- There is a critical need for new biomarkers to improve early diagnosis and treatment options, as many patients experience recurrence.
- The review focuses on deubiquitinating enzymes (DUBs) that regulate protein stability in ovarian cancer, which could aid in the identification of potential biomarkers and therapeutic targets.
Article Abstract
In ovarian cancer patients, the 5-year survival rate is 90% for stages I and II, but only 30% for stages III and IV. Unfortunately, as 75% of the patients are diagnosed at stages III and IV, many experience a recurrence. To ameliorate this, it is necessary to develop new biomarkers for early diagnosis and treatment. The ubiquitin-proteasome system is a post-translational modification that plays an important role in regulating protein stability through ubiquitination. In particular, deubiquitinating enzymes (DUBs) regulate protein stability through deubiquitinating substrate proteins. In this review, DUBs and substrates regulated by these enzymes are summarized based on their functions in ovarian cancer cells. This would be useful for the discovery of biomarkers for ovarian cancer and developing new therapeutic candidates.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137459 | PMC |
| http://dx.doi.org/10.3390/genes14040886 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!